Ipsen S.A. (IPN.PA) fair value

ACCE thesis

Ipsen is a French specialty pharma company whose revenue comes mainly from oncology and rare-disease products, with its Somatuline (lanreotide) franchise for neuroendocrine tumours and acromegaly among its largest lines, alongside Dysport for neurological and aesthetic uses. The advantage is that these are niche, hard-to-replicate indications where prescribers are concentrated and generic entry is a long way off, which supports the 81.0% gross margin and 28.5% operating margin. Revenue growth of 18.7% gives the company a clear top-line engine, and the next leg depends on new launches and label expansions in oncology, where the pipeline, not the existing franchise, will decide whether that growth persists. The stock looks interesting now because the trailing P/E of 24.6 compresses to a forward P/E of 10.9, a gap that implies the market is either doubting earnings growth continues or is discounting the durability of the Somatuline cash flows, and that disagreement is worth testing. The 11.4% ROE is modest against those margins, which points to a balance sheet or capital intensity question that needs a deeper look before anyone draws a conclusion.